|
gptkbp:instanceOf
|
Neuroendocrine Tumor
|
|
gptkbp:alsoKnownAs
|
gptkb:islet_cell_tumors
pancreatic endocrine tumors
|
|
gptkbp:associatedWith
|
gptkb:Multiple_Endocrine_Neoplasia_type_1
gptkb:Neurofibromatosis_type_1
gptkb:Tuberous_sclerosis
gptkb:Von_Hippel-Lindau_disease
|
|
gptkbp:canBeFunctional
|
true
|
|
gptkbp:canBeNonfunctional
|
true
|
|
gptkbp:canMetastasizeTo
|
gptkb:cancer
gptkb:bone
liver
lymph nodes
|
|
gptkbp:canSecreteHormones
|
gptkb:glucagon
gptkb:VIP
gptkb:gastrin
gptkb:insulin
gptkb:somatostatin
gptkb:ACTH
|
|
gptkbp:category
|
pancreatic tumor
endocrine tumor
|
|
gptkbp:diagnosedBy
|
gptkb:CT_scan
MRI
biopsy
chromogranin A test
|
|
gptkbp:firstDescribed
|
1907
|
|
gptkbp:fullName
|
gptkb:pancreatic_neuroendocrine_tumors
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PanNETs
|
|
gptkbp:ICD-10_code
|
C25.4
|
|
gptkbp:incidence
|
rare
|
|
gptkbp:location
|
pancreas
|
|
gptkbp:mostCommonFunctionalType
|
gptkb:insulinoma
|
|
gptkbp:mostCommonNonfunctionalType
|
nonfunctional PanNET
|
|
gptkbp:percentageOfPancreaticTumors
|
1-2%
|
|
gptkbp:prognosis
|
functionality
tumor stage
tumor grade
|
|
gptkbp:symptom
|
gptkb:diabetes
abdominal pain
jaundice
weight loss
|
|
gptkbp:treatment
|
gptkb:somatostatin_analogs
surgery
chemotherapy
radiotherapy
targeted therapy
|
|
gptkbp:WHOClassification
|
poorly-differentiated neuroendocrine carcinoma
well-differentiated neuroendocrine tumor
|
|
gptkbp:bfsParent
|
gptkb:pancreatic_neuroendocrine_tumors
|
|
gptkbp:bfsLayer
|
6
|